TY - JOUR
T1 - Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase
T2 - Comparative safety profiles of newer agents
AU - Kelly, Kevin
AU - Swords, Ronan
AU - Mahalingam, Devalingam
AU - Giles, Francis J.
PY - 2010/8/1
Y1 - 2010/8/1
N2 - Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.
AB - Imatinib is broadly used in the frontline treatment of chronic myeloid leukemia (CML). Although long-term safety and efficacy have been established, some patients will not respond to imatinib. Nilotinib and dasatinib successfully recapture responses for most patients with imatinib-refractory or -intolerant disease. These drugs have different safety profiles, which are likely associated with their divergent inhibitory targets. The presence of BcrAbl mutations and safety profiles of available therapies in relation to patient history should be considered when choosing a second-line agent. This review evaluates the safety and tolerability of agents approved for CML treatment and briefly discusses newer third-line agents.
KW - Imatinib
KW - chronic myeloid leukemia
KW - dasatinib
KW - nilotinib
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=77955443343&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955443343&partnerID=8YFLogxK
U2 - 10.3109/10428194.2010.491135
DO - 10.3109/10428194.2010.491135
M3 - Review article
C2 - 20528247
AN - SCOPUS:77955443343
VL - 51
SP - 1399
EP - 1413
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 8
ER -